Pannus

Krystal Biotech Announces Publication in the New England Journal of Medicine on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis Bullosa

Retrieved on: 
Thursday, February 8, 2024
Manuscript, KRYS, Paratriathlon, Pannus, Patient, Disease management, Scar, Ophthalmology, FDA, Abrasion, Concha bullosa, DEB, Risk, Research and development, Gene, Blister, Associate, Suma, Doctor of Philosophy, NEJM, Eye, Pharmaceutical industry

PITTSBURGH, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced data on the compassionate use of beremagene geperpavec (B-VEC), administered as an eyedrop to treat a patient with dystrophic epidermolysis bullosa (DEB) with cicatrizing conjunctivitis has been published in the New England Journal of Medicine (NEJM). The full manuscript, titled “Ocular Gene Therapy in a Patient with Dystrophic Epidermolysis Bullosa,” can be found in the February 8, 2024 issue of the NEJM.

Key Points: 
  • The full manuscript, titled “Ocular Gene Therapy in a Patient with Dystrophic Epidermolysis Bullosa,” can be found in the February 8, 2024 issue of the NEJM.
  • Over 25% of patients with DEB develop ocular complications such as corneal erosions, abrasions, blistering and scarring that can lead to impaired vision.
  • The NEJM publication describes the first application of B-VEC to treat ocular complications in a patient with DEB under a compassionate use program.
  • If approved, this approach could drastically benefit these patients.”
    A patient presented with severe cicatrizing conjunctivitis secondary to DEB.

Krystal Biotech Announces First Quarter 2023 Financial Results and Operational Highlights

Retrieved on: 
Monday, May 8, 2023
NCT, Netherton syndrome, Cohort, European Medicines Agency, Ministry of Health, Labour and Welfare, Cystic fibrosis, Phase 1, Investment, Patient, Cystic Fibrosis Foundation, TGM1, Ministry of Health (Saudi Arabia), Association for Research in Vision and Ophthalmology, ARVO, Prescription Drug User Fee Act, Pannus, AATD, Rare, Jeune, FDA, IND, Skin, Safety, PIP, RDEB, Eye, Ministry, Financial result, Form, Research, Therapy, KRYS, DEB, MHLW, Clinical trial, Marketing, Annual general meeting, Pharmaceutical industry, Maple syrup, Ophthalmology, PDUFA, Health

Financial results for the quarter ended March 31, 2023:

Key Points: 
  • Financial results for the quarter ended March 31, 2023:
    Cash, cash equivalents, and investments totaled $355.5 million on March 31, 2023.
  • Research and development expenses for the quarter ended March 31, 2023 were $12.3 million, compared to $9.3 million for the quarter ended March 31, 2022.
  • General and administrative expenses for the quarter ended March 31, 2023 were $24.0 million, compared to $15.9 million for the quarter ended March 31, 2022.
  • For additional information on the Company’s financial results for the quarter ended March 31, 2023, please refer to the Form 10-Q filed with the SEC.

Krystal Biotech Announces Clinical Data on Topical Application of B-VEC to the Eye to Treat Ocular Complications in a Patient with Dystrophic Epidermolysis Bullosa Under a Compassionate Use Program

Retrieved on: 
Monday, April 24, 2023
Slit lamp, KRYS, Corneal abrasion, ARVO, DEB, Research and development, University, AE, Hospital, Eye, Suma, Doctor of Philosophy, Assistant, Concha bullosa, Bascom Palmer Eye Institute, Pannus, Ophthalmology, HM, Patient, Association for Research in Vision and Ophthalmology, Rare, Research, FDA, Visual acuity, Pharmaceutical industry, Telescopic sight

“It is exciting to potentially advance a topical treatment for patients with ocular complications associated with DEB.”

Key Points: 
  • “It is exciting to potentially advance a topical treatment for patients with ocular complications associated with DEB.”
    The data presented describes the first application of B-VEC to treat ocular complications in a patient with DEB under a compassionate use program.
  • The patient presented with cicatrizing conjunctivitis and underwent surgical symblepharon lysis with pannus removal in the right eye.
  • B-VEC was administered to the patient’s right eye at regular intervals following surgery in addition to routine post-surgical management.
  • Ocular complications are common in patients with DEB, with over half of the patients diagnosed with recessive DEB potentially affected.

Enosi Life Sciences Files Patent for TNF-Inhibiting Molecules EN1001, EN2001 and EN3001

Retrieved on: 
Wednesday, November 18, 2020
Medicine, Medical specialties, Health, Autoimmunity, Immunology, Autoimmune disease, Pannus, Cancer

These include EN1001 for autoimmune disease; EN2001 for autoimmune disease and cancer; and EN3001 for autoimmune disease and cancer.

Key Points: 
  • These include EN1001 for autoimmune disease; EN2001 for autoimmune disease and cancer; and EN3001 for autoimmune disease and cancer.
  • Enosi has shown that its lead molecule (EN2001), which traps these growth factors, can prevent tissue destruction by inhibiting the growth of cells that form the pannus.
  • These three therapeutics from Enosi; EN1001, EN2001 and EN3001 are still in development and are at least five years away from clinical trials.
  • About Enosi Life Sciences Corp.
    Enosi Life Sciences Corp. is a drug research and development company focused on providing industry-leading therapeutics for autoimmune diseases and cancer.